Wiskott-Aldrich Syndrome – Disease Requiring Early Transplantation of Hemopoietic Stem Cells
Authors:
R. Formánková 1; P. Sedláček 1; T. Freiberger 3,4; J. Bartůňková 2; A. Šedivá 2; E. Mejstříková 1; P. Keslová 1; B. Ravčuková 3; V. Vávra 1; J. Litzman 4; E. Pařízková 5; Y. Jabali 6; H. Schneiderová 7; J. Starý 1
Authors‘ workplace:
Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Praha
přednosta prof. MUDr. J. Starý, DrSc.
1; Ústav imunologie UK 2. LF a FN Motol, Praha
přednostka prof. MUDr. J. Bartůňková, DrSc.
2; Genetická laboratoř Centra kardiovaskulární a transplantační chirurgie, Brno
vedoucí MUDr. T. Freiberger, PhD.
3; Ústav klinické imunologie a alergologie LF MU a FN u Sv. Anny, Brno
přednosta prof. MUDr. J. Litzman, CSc.
4; Dětská klinika LF UK a FN, Hradec Králové
přednosta prof. MUDr. M. Bayer, CSc.
5; Dětské oddělení Nemocnice České Budějovice
primář MUDr. V. Smrčka
6; II. dětská klinika FN Brno
přednosta prof. MUDr. Z. Doležel, CSc.
7
Published in:
Čes-slov Pediat 2009; 64 (3): 106-114.
Category:
Original Papers
Overview
Wiskott-Aldrich syndrome (WAS) is a rare disease characterized by thrombocytopenia with small platelets, combined immunodeficiency and eczema. The disease is caused by the WASP gene, which is localized on chromosome X and is coding multifunctional intracellular protein WASp. The disease becomes clinically manifest by skin hemorrhage manifestations, epistaxis events, as well as bleeding from gingival and intestines exanthema and recurrent respiration infections. Increased occurrence of autoimmune diseases and malignancies was observed in patients with WAS.
WAS is a very rare disease and because of that the diagnostics is not easy even at the present time. The diagnosis of WAS is to be considered in all cases of thrombocytopenia in combination with eczema and relapsing respiratory infections, small thrombocytes are typical for diagnosis. In the case of suspected WAS the child patient should be admitted to hematological center as early as possible and the center should confirm the diagnosis in collaboration with an immunological workplace together with molecular genetic examination and initiates the search for HLA-identical donor. The problem of necessary correct and early establishment of diagnosis is documented on case histories of 6 patients handed over to our workplace and indicated to allogenic transplantation of hemopoietic stem cells (SCT) in the years 1996-2007. SCT is presently the only possibility to cure up WAS and the successfulness is markedly dependent on early establishment of diagnosis and efficient prophylaxis and directed therapy of infectious complications.
Key words:
Wiskott-Aldrich syndrome, WASP gene, thrombocytopenia, eczema, primary immunodeficiency, transplantation of hemopoietic stem cells
Sources
1. Wiskott A. Familial congenital Morbus Werlhoffi? Monatsschr. Kinderheilkd. 1937;68: 212–216.
2. Aldrich RA, Steinberg AG, Campbell DC, et al. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 1954;13: 133–139.
3. Sullivan KE, Mullen CA, Blaese RM, et al. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 1994;125: 876–885.
4. Ochs HD, Trasher J. The Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 2006;117: 725–738.
5. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry at the National Marrow Donor Program. Blood 2001;97: 1598–1603.
6. Cooper MD, Chae HP, Lowman JT, et al. Wiskott-Aldrich syndrome: an immunological deficiency disease involving the afferent limb of immunity. Am. J. Med. 1968;44: 499–513.
7. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78: 635–644.
8. Villa A, Notarangelo L, Macchi P, et al. X-linked trombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat. Genet. 1995;9: 414–417.
9. Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr. Opin. Hematol. 2005;12: 284–291.
10. Ochs HD. The Wiskott-Aldrich syndrome. Isr. Med. Assoc. J. 2002;4: 379–384.
11. Jin Y, Mazza C, Christie JR, et al. Mutation of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription and translation and phenotype/genotype correlation. Blood 2004;104: 4010–4019.
12. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111: 439–445.
13. Burns S, Cory GO, Vainchenker W, et al. Mechanisms of WASp-mediated hematologic and immunologic disease. Blood 2004;104: 3456–3462.
14. Park JY, Kob M, Prodeus AP, et al. Early deficit of lymphocytes in Wiskott-Aldrich syndrome: possible role of WASP in human lymphocyte maturation. Clin. Exp. Immunol. 2004;136: 104–110.
15. Yamada M, Ohtsu M, Kobayashi I, et al. Flow cytometric analysis of Wiskott-Aldrich syndrome (WAS) protein in lymphocytes from WAS patients and their familial carriers. Blood 1999;93: 756–757.
16. Kwan SP, Lehner T, Hagemann T, et al. Localization of the gene for the Wiskott-Aldrich syndrome between two flanking markers, TIMP and DXS255, on Xp11.22-Xp11.3. Genomics 1991;10: 29–33.
17. Notarangelo LD, Mazza C, Viliami S, et al. Missense mutations of WASP gene cause intermitent X-linked trombocytopenia. Blood 2002;99: 2268–2269.
18. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Current Opinion in Hematology 2008;15: 30–36.
19. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006;108: 2182–2189.
20. Imai I, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004;103: 456–464.
21. Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007;110: 2209–2214.
22. Charrier S, Dupre L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 2007;14: 415–428.
23. Dupre L, Marangoni F, Scaramuza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum. Gene Ther. 2006;17: 303–313.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2009 Issue 3
Most read in this issue
- Insulinoma – the Cause of Relapsing Hypoglycemia in a 16-year Patient
- Disorder of Growth and Development in a Boy with X-bound Ichthyosis, Protracted Delivery and Low Level of Estriol in the Mother during Pregnancy
- Wiskott-Aldrich Syndrome – Disease Requiring Early Transplantation of Hemopoietic Stem Cells
- Food-induced Anaphylaxis in Children